Alzheimer Disease, Postmenopausal Symptoms
Conditions
Brief summary
The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid. The degradation products in blood will be analysed during the trial, to get better insight in menopause and the start of hormonal therapy. Postmenopausal women with and without history of breast cancer will be recruited for the trial.
Interventions
PROCEDUREblood take
Blood is taken to analyse degradation products of the metabolism of amyloid
Sponsors
University Hospital, Ghent
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
10 study groups: 9 groups who start with hormonal treatment and 1 control group who doesn't start with hormonal treatment
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* postmenopausal women * 40 - 65 years
Exclusion criteria
* Longer than 10 years in menopause * thyroid dysfunction * hypertension * medical history of psychiatric comorbidity * Alcohol and/or drug abuse * medical history of neurologic symptoms with cognitive symptoms
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Degradation products of the Amyloid metabolism in blood | 2 years after the first patient was included, the first batch of samples will be analysed. | The influence of hormone treatment (menopause) and anti-hormone treatment (breastcancer) on the amyloid metabolism and the development of Alzheimer will be evaluated. Different laboratory analysis will be performed to evaluate the degradation products of the metabolism of amyloid in blood. Different parts of the degradation products will be analysed namely: Plasma total-tau |
| APOE-genotyping in blood | 2 years after the first patient was included, the first batch of samples will be analysed. | The influence of hormone treatment (menopause) and anti-hormone treatment (breastcancer) on the amyloid metabolism and the development of Alzheimer will be evaluated. APOE-genotyping will be performed |
| identify BACE1 in blood | 2 years after the first patient was included, the first batch of samples will be analysed. | The influence of hormone treatment (menopause) and anti-hormone treatment (breastcancer) on the amyloid metabolism and the development of Alzheimer will be evaluated. BACE1 will also be identified in the blood. |
Countries
Belgium
Contacts
Primary ContactEline Meireson, Msc
Outcome results
None listed